OBJECTIVES: The objective of our study was to assess health status among women suffering from CVD. METHODS: Symptomatic women patients suffering from CVD (CEAP clinical classes C0 to C4), aged over 18, newly treated by their GP with a phlebotropic drug were enrolled in the study. Every patient hadto complete a self-questionnaire including the SF-12 scale at day 0, day 3 and day 7. The SF-12 is a generic measure of health statusThe SF-12 is composed of two dimensions, a Physical Component Summary (PCS-12) and a Mental component Summary (MCS-12). The results are standardised on the general US population (mean score of 50 (SD=10)) so results for 1 can be meaningfully compared with the other. The lower the score is the worse is the impact on patients’ quality of life. RESULTS: This analysis includes the first 399 patients assessed at day 0, day 3 and day 7. The mean age was 45.0 years old (SD=11, n=370). At inclusion time (n=374), MCS-12 and PCS-12 were respectively 44.7 (SD=10.6) and 46.4 (SD=8.4): at day 3 and day 7, these dimensions were respectively: D3: 46.5 (SD=10.2) and 46.2 (SD=8.0) D7: 48.0 (SD=10.3) and 46.2 (SD=7.8). For the mental dimension, the difference was statistically significant (p=0.0001). CONCLUSIONS: These results suggest that CVD has a great impact on women. The SF-12 mean scores were below those of the age- and gender-matched general population. The patient management and the use of a phlebotropic drug demonstrated an improvement on the mental health status of the patient and a decrease of the impact of pain interfering with patients normal work.